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Background: Ostial left anterior descending coronary artery (LAD) lesion has been regarded as a 36 
lesion subset unsuitable for coronary stenting. Long-term outcomes of sirolimus-eluting stent (SES) 37 
implantation for ostial LAD lesions have not been yet adequately evaluated. 38 
Methods and Results: Among 12824 patients enrolled in the j-Cypher registry, 3-year outcomes 39 
were compared between 481 patients with SES-treated ostial LAD lesions and 5369 patients with 40 
SES-treated non-ostial proximal LAD lesions. Patients with ostial LAD lesions, as compared with 41 
patients with non-ostial proximal LAD lesions, had similar incidences of target lesion 42 
revascularization (TLR) (9.4% vs. 9.7%, p=0.98; adjusted hazard ratio (HR) 0.99 (95% confidence 43 
interval (CI): 0.7-1.36), p=0.94) and death/myocardial infarction (MI) (10.7% vs. 11.4%, p=0.82; 44 
adjusted HR 1.05 (95%CI: 0.76-1.4), p=0.77), respectively. Among 481 patients with ostial LAD 45 
lesions, patients undergoing both main- and side-branch stenting (62 patients), as compared with 46 
main-branch stenting alone (419 patients), had higher risk for TLR (adjusted HR 4.65 (95%CI: 47 
2.32-9.25), p < 0.0001) but had similar risk for death/MI (adjusted HR 1.15 (95%CI: 0.49-2.41), 48 
p=0.73). In patients with main-branch stenting alone, outcomes after crossover-stenting across 49 
circumflex (225 patients) were not different from those after ostial-stenting (194 patients) (adjusted 50 
HR 0.77 (95%CI: 0.33-1.82), p=0.55 for TLR, and adjusted HR 1.54 (95%CI: 0.78-3.2), p=0.22 for 51 
death/MI).  52 
Conclusions: In terms of both safety and efficacy, 3-year outcomes of PCI using SES for ostial LAD 53 
lesions were comparable to those for non-ostial proximal LAD lesions. Crossover-stenting with 54 
4 
 
one-stent approach might be a reasonable option in treating ostial LAD lesions.  55 
 56 




The ostial left anterior descending coronary artery (LAD) lesion is an important target for coronary 59 
revascularization, since this lesion location subtends a large territory of myocardium. However, the 60 
ostial LAD lesion has been regarded as a lesion subset unsuitable for percutaneous coronary 61 
intervention (PCI) because of frequent atherosclerotic involvement of distal left main coronary 62 
artery (LMCA) and because of concerns for compromising the circumflex coronary artery (LCX). 63 
Furthermore, restenosis rate after implantation of bare-metal stents (BMS) for ostial LAD lesions 64 
remained high, ranging from 26% to 33% 
1,2)
. Although randomized controlled trials comparing 65 
drug-eluting stents (DES) with BMS demonstrated significant reduction in the rates of target-lesion 66 
revascularization (TLR) with use of DES, ostial LAD lesions have been excluded from most of 67 
these randomized controlled trials. Despite increasingly frequent use of DES for the treatment of 68 
ostial LAD lesions, its long-term outcome has not been yet adequately evaluated 
3-5)
. The current 69 
analysis was conducted to evaluate 3-year clinical outcomes of patients who underwent 70 
sirolimus-eluting stents (SES) implantation for ostial LAD lesions in a large cohort of patients 71 
enrolled in the j-Cypher registry. 72 
Methods 73 
Study Design and Patient Population 74 
The study design for the j-Cypher registry was previously described 
6)
. In brief, the 75 
j-Cypher registry is a physician-directed, prospective, multicenter registry in Japan enrolling 76 
consecutive patients undergoing SES implantation without any exclusion criteria (Supplemental 77 
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Appendix A). While a center actively enrolled patients, technicians in the catheterization laboratory 78 
registered all the patients undergoing PCI in a screening log. When SES implantation was 79 
undertaken, the patient was invited to participate in the j-Cypher registry. Although data entry was 80 
basically left to the individual sites, the experienced clinical research coordinators (Supplemental 81 
Appendix B) in the data management center  supported data entry when necessary. Logical 82 
inconsistencies were resolved by inquiries to the site investigators and/or by audits against the 83 
original data sources. Follow-up data were obtained from hospital charts or by contacting patients 84 
and/or referring physicians at 30 days, 6 months, one year and yearly thereafter. When death, 85 
myocardial infaction (MI), and stent thrombosis (ST) were reported, the events were adjudicated 86 
using the original source documents by a clinical events committee (Supplemental Appendix C). 87 
Adjudication of TLR events was left to the decision of the local investigators. The relevant review 88 
boards in all 37 participating centers approved the study protocol. Written informed consent was 89 
obtained from all patients enrolled.  90 
The current pre-specified sub-analysis from the j-Cypher registry was intended to evaluate 91 
safety and efficacy of SES use in patients with ostial LAD lesions. Among 12824 patients enrolled 92 
in the j-Cypher registry from August 2004 to November 2006, 6230 patients underwent PCI for 93 
proximal LAD disease. Excluding 380 patients in whom proximal LAD lesions were treated by 94 
modalities other than SES, the current study population consisted of 5850 patients whose proximal 95 
LAD lesions were treated exclusively with SES. Baseline characteristics and clinical outcomes were 96 
compared between 481 patients with ostial LAD lesions, and 5369 patients with non-ostial proximal 97 
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LAD lesions. Subgroup analysis was also conducted in 481 patients whose ostial LAD lesions were 98 
treated exclusively by SES. Baseline characteristics and clinical outcomes were compared between 99 
main-branch stenting alone (one-stent approach; 419 patients) and both main- and side-branch 100 
stenting (two-stent approach; 62 patients). Furthermore, in patients with one-stent approach, baseline 101 
characteristics and clinical outcomes were compared between crossover stenting across LCX 102 
(crossover-stenting; 225 patients) and stenting just at the ostium of LAD (ostial-stenting; 194 103 
patients) (Figure 1). 104 
Definitions  105 
A “lesion” was defined as the area covered by single or multiple overlapping stents. When 106 
two stents were placed without overlap, these two areas were regarded as two separate lesions. Ostial 107 
lesion was defined as a narrowing located within 3 mm of the vessel origin in the least foreshortened 108 
angiographic projection. Those ostial LAD lesions with concomitant significant LMCA distal bifurcation 109 
stenosis were regarded as LMCA lesions and were excluded from the current analysis. Proximal LAD 110 
was defined as the segment of LAD proximal to the first major septal branch. Techniques of stenting were 111 
pre-specified and recorded in the case report forms during the index stent implantation procedures. 112 
Crossover-stenting was defined as stent placement from distal LMCA to LAD across LCX, while 113 
ostial-stenting as the stenting strategy with an intention not to protrude the stent into LMCA. 114 
One-stent approach meant stenting of LAD only (including crossover-stenting and ostial-stenting) 115 
and two-stent approach denoted stenting of both ostial LAD and ostial LCX. Choice of the stenting 116 
strategies was left to the discretion of the operators.  117 
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The primary outcome measure for efficacy in the current analysis was defined as TLR for 118 
the index proximal LAD lesions. TLR was defined as either PCI or coronary artery bypass grafting 119 
(CABG) surgery due to restenosis or thrombosis of the target lesion that included the proximal and 120 
distal edge segments as well as the ostium of the side branches. The composite of death or MI was 121 
selected as the primary outcome measure for safety. Death was regarded as cardiac in origin unless 122 
obvious non-cardiac causes could be identified. Any death during the index hospitalization was 123 
regarded as cardiac death. Sudden death was defined as unexplained death in previously stable 124 
patients. MI was adjudicated according to the definition in the Arterial Revascularization Therapy 125 
Study 
7)
. ST was defined according to the Academic Research Consortium (ARC) definition 
8)
. 126 
Statistical Analysis 127 
Categorical variables are presented as counts and percentages, and were compared with the 128 
chi-square test. Continuous variables were expressed as mean value ± SD unless otherwise indicated. 129 
Continuous variables were compared with the Student t test or Wilcoxon rank sum test on the basis 130 
of their distribution. Cumulative incidences of events were estimated by the Kaplan–Meier method, 131 
and curves were compared with the log-rank test. A multivariable Cox proportional hazard model 132 
was developed to adjust the differences in baseline characteristics. Proportional hazard assumptions 133 
for variables were assessed on the plots of log (time) versus log [-log (survival)] stratified by the 134 
variables, and were found justified. For the multivariable analysis, we first selected variables with p 135 
values < 0.1 in the univariate Cox models among 21 independent variables used in the previous 136 
report 
6)
. In the final multivariable model, we incorporated ostial LAD vs. non-ostial proximal LAD, 137 
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or one-stent approach vs. two-stents approach, and crossover-stenting vs. ostial-stenting together 138 
with those independent variables with multivariable p values < 0.05. Covariates used in the final 139 
model for adjustment were indicated in Supplemental Tables 1-3. The results of the multivariable 140 
analysis were expressed as adjusted hazard ratios (HR) and their 95% confidence intervals (CI).  141 
Statistical analyses were conducted by two physicians (Kishi K and Kimura T) and a statistician 142 
(Morimoto T) with the use of JMP 8.0 (SAS Institute Inc, Cary, NC) software. P values < 0.05 were 143 
considered statistically significant. 144 
Results 145 
Baseline Characteristics: Ostial LAD vs. Non-ostial Proximal LAD 146 
The baseline clinical characteristics were generally similar between the ostial LAD group 147 
and the non-ostial proximal LAD group, although patients >= 80 years of age, patients with prior MI 148 
and statin users were more prevalent in the ostial LAD group (Table 1-A). The baseline angiographic 149 
and procedural data were significantly different between the two groups (Table 1-B). The ostial 150 
LAD group had larger vessel size, resulting in use of stents and balloons with bigger sizes. 151 
Directional coronary atherectomy (DCA) before stenting, intravascular ultrasound (IVUS), and post 152 
dilatation were more frequently utilized in the ostial LAD group. Minimal lumen diameter (MLD) 153 
post procedure was significantly larger in the ostial LAD group. 154 
Clinical Outcomes: Ostial LAD vs. Non-ostial proximal LAD  155 
The follow-up interval in surviving patients was significantly longer in patients with ostial 156 
LAD lesions (median: 995 days; interquartile range (IQR): 732 to 1095 days) than in patients with 157 
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non-ostial proximal LAD lesions (median: 904 days; IQR: 730 to 1095 days) (P=0.02). Follow-up at 158 
1 year was completed in 97% of patients.  159 
Cumulative incidence of TLR in the ostial LAD group was not different from that in the 160 
non-ostial proximal LAD group (9.4% vs. 9.7%, p=0.98) (Table 2 and Figure 2-A). Adjusted 161 
hazard ratio of ostial LAD vs. non-ostial proximal LAD for TLR was 0.99 (95% CI: 0.7-1.36, 162 
p=0.94). Similarly, cumulative incidences of death or MI were not significantly different between 163 
the two groups (10.7% vs. 11.4%, p=0.82) (Figure 2-B). Adjusted hazard ratio of ostial LAD vs. 164 
non-ostial proximal LAD for death or MI was 1.05 (95% CI: 0.76-1.4, p=0.77).  165 
Baseline Characteristics: One-stent vs. Two-stent approach  166 
The baseline clinical characteristics were generally similar between the one-stent approach 167 
group and the two-stent approach group, although patients >= 80 years of age were more prevalent 168 
in the two-stent approach group (Supplemental Table 4-A). The baseline procedural and 169 
angiographic data were significantly different between the two groups. Crossover stenting approach 170 
and final kissing balloon technique were more frequently utilized in the two-stent approach group. 171 
The number and length of stents were greater in the two-stent approach group. Obviously, the 172 
prevalence of significant narrowing at the ostium of LCX was markedly higher in the two-stent 173 
approach group. Reference diameter (RD) and MLD of LCX before procedure were significantly 174 
smaller in the two-stent approach group than in the one-stent approach group. Despite these 175 
differences in procedural and angiographic characteristics, post-procedural MLD in the main branch 176 
did not differ between the two groups. Final MLD of LCX was significantly larger in the two-stent 177 
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approach group than in the one-stent approach group. (Supplemental Table 4-B) 178 
Clinical Outcomes: One-stent vs. Two-stent Approach  179 
Cumulative incidence of TLR in the two-stent group was significantly higher than that in 180 
the one-stent group (28.1% vs. 6.6%, p<0.0001) (Table 3 and Figure 3-A). The adjusted hazard ratio 181 
of the two-stent approach vs. one-stent approach for TLR was 4.65 (95% CI: 2.32-9.25, p<0.0001). 182 
Cumulative incidences of stroke, CABG, and any coronary revascularization were also significantly 183 
higher in the two-stent group than those in the one-stent group. However, cumulative incidences of 184 
death or MI were not significantly different between the two groups (16.8% vs. 9.8%, p=0.37) 185 
(Table 3 and Figure 3-B). Adjusted hazard ratio of two-stent approach vs. one-stent approach for 186 
death or MI was 1.15 (95% CI: 0.49-2.41, p=0.73).  187 
Baseline Characteristics: Crossover-stenting vs. Ostial-stenting 188 
Although the baseline clinical characteristics were generally similar between the 189 
ostial-stenting group and the crossover-stenting group, the latter included more male patients and 190 
patients with prior heart failure (Supplemental Table 5-A). The baseline procedural and angiographic 191 
data were significantly different between the two groups. Final kissing balloon technique was more 192 
frequently utilized in the crossover-stenting group, reflecting greater prevalence of significant 193 
narrowing at the ostium of LCX. Although the crossover-stenting group had larger stent size, larger 194 
maximum balloon size and longer stent length, post-procedural MLD in the main branch did not 195 
differ between the two groups. Final MLD of LCX was significantly smaller in the 196 
crossover-stenting group than in the ostial-stenting group. (Supplemental Table 5-B) 197 
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Clinical Outcomes: Crossover-stenting vs. Ostial-stenting 198 
Cumulative incidences of TLR were not significantly different between the crossover-stenting 199 
group and the ostial-stenting group (5.4% vs. 7.9%, p=0.81) (Table 4 and Figure 4-A). Adjusted 200 
hazard ratio of crossover-stenting vs. ostial-stenting for TLR was 0.77 (95% CI: 0.33-1.82, p=0.55). 201 
Similarly, cumulative incidences of death or MI were not significantly different between the two 202 
groups (12.2% vs. 7.0%, p=0.07) (Table 4 and Figure 4-B). Adjusted hazard ratio of 203 
crossover-stenting vs. ostial-stenting for death or MI was 1.54 (95% CI: 0.78-3.2, p=0.22). 204 
Although the crude incidence of all-cause death was significantly higher in the crossover-stenting 205 
group (12.2% vs. 4.5%, p=0.01), the difference was no longer significant after adjusting 206 
confounders (adjusted HR 2.04 [95% CI: 0.94-4.93, p = 0.07]) (Table 4). 207 
Discussion 208 
The main findings of the current analysis in the largest ever reported series of patients 209 
undergoing SES implantation for ostial LAD lesions are as follows: (1) In terms of both safety and 210 
efficacy, 3-year outcomes of PCI using SES for ostial LAD lesions were comparable to those for 211 
non-ostial proximal LAD lesions; (2) The two-stent approach, as compared with the one-stent 212 
approach, was associated with significantly higher rate of TLR; and (3) Clinical outcomes after 213 
crossover-stenting with one-stent approach for ostial LAD lesions were similar to those after 214 
ostial-stenting.  215 
Drawbacks of BMS Implantation for Ostial LAD Lesions 216 
Ostial LAD lesion has historically been regarded as a lesion subset unsuitable for PCI using 217 
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coronary stents. One of the shortcomings of coronary stenting for ostial LAD lesions was the 218 
potential for compromising LCX either by plaque shifting or by pinching the LCX ostium. When 219 
the ostium of LCX had already been significantly narrowed before the procedure, stenting of both 220 
LAD and LCX might be the only way to optimize the final angiographic result. However, in the era 221 
of BMS, stenting both main- and side-branches was considered to be contraindicated in treating 222 
bifurcation lesions due to unacceptably high restenosis rate 
9)
. Also, ostial LAD lesions are often 223 
contiguous with the distal LMCA disease, even if the LMCA lesions are not angiographically 224 
significant. Progression of the LMCA lesions subsequent to the injuries during stent implantation 225 
procedure had been another potential concern related to coronary stenting for ostial LAD lesions. 226 
Furthermore, it is technically demanding to place a stent just at the ostium of LAD without missing 227 
the adequate coverage of the lesion and without excessive protrusion into the distal LMCA 228 
bifurcation. Therefore, surgical revascularization could still be considered in patients with ostial 229 
LAD lesions even if they have single-vessel coronary artery disease. 230 
Outcomes of DES Implantation for Ostial LAD Lesions 231 
Despite increasingly frequent use of DES for the treatment of ostial LAD lesions, there are only 232 
a few small previous studies evaluating the outcome of DES implantation for ostial LAD lesions. 233 
Seung et al. compared the clinical outcome of 68 consecutive patients undergoing SES implantation 234 
with that of 77 historic control patients undergoing BMS implantation 
3)
. The rate of TLR at 1 year 235 
was reported to be less frequent in the SES group than in the BMS group (0% vs. 17%, p < 0.001). 236 
Tsagalou et al. compared the clinical outcome of 43 consecutive patients undergoing DES 237 
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implantation with that of 43 historic control patients undergoing BMS implantation 
4)
. The rate of 238 
TLR at 9 months was reported to be less frequent in the DES group than in the BMS group (7% vs. 239 
25.6%, p < 0.001). Our current analysis evaluating larger number of patients clearly demonstrated 240 
that the rate of TLR at 3 years after SES implantation in patients with ostial LAD lesions was 241 
comparable to that in patients with non-ostial proximal LAD lesions, in whom PCI using DES has 242 
been regarded as the standard of care. The incidences of death or MI were also similar between 243 
patients with ostial LAD lesions and patients with non-ostial proximal LAD lesions, suggesting 244 
safety of PCI using SES for the ostial LAD lesions. 245 
Stent Implantation Techniques for Ostial LAD Lesions  246 
Relatively high restenosis rate in ostial lesions might be related to incomplete lesion coverage 247 
due to the technical difficulties in stent positioning in this lesion location. Encouraged by the 248 
favorable outcomes after unprotected LMCA stenting with DES, crossover-stenting technique 249 
emerged as a new stenting strategy for the ostial LAD lesions 
3, 5, 10, 11)
. In the current analysis, 250 
crossover-stenting was adopted in 56% of patients undergoing SES implantation for ostial LAD 251 
lesions. Cumulative incidences of TLR and death or MI after crossover-stenting were not different 252 
from those after ostial-stenting, suggesting safety and efficacy of crossover-stenting in selected 253 
anatomic situations. The Crossover-stenting technique enabling easier stent positioning and full 254 
coverage of the lesion seemed to be particularly relevant in treating those ostial LAD lesions with 255 
concomitant distal LMCA disease.   256 
In the current analysis, the rate of TLR in patients who underwent stenting of both main- and 257 
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side-branches was unacceptably high, as was reported for unprotected LMCA stenting 
12)
. Although 258 
we could not address the safety issues of the two-stent approach due to the small sample size, it 259 
would be too premature to promote PCI using DES in patients in whom the two-stent approach is 260 
likely to be required.  261 
Study Limitations 262 
There are several important limitations in this study. First, we do not have the control 263 
group of patients treated by CABG. However, single digit TLR rate at 3 years after PCI seems to be 264 
clinically acceptable even if we do not have the surgical control patients. Second, the choices 265 
regarding treatment strategies for the ostial LAD lesions were left to discretion of the operators and 266 
were not based on randomized assignment. Treatment strategies were chosen according to the 267 
various anatomic features of the ostial LAD lesions. Therefore, the comparison between the 268 
crossover-stenting and the ostial stenting may not be clinically relevant. Also, we could not address 269 
the issue of optimal two-stent technique due to small number of patients treated with two-stent 270 
approach. Third, angiograms were not analyzed by a core angiographic laboratory and therefore, 271 
the adjudication of ostial lesion was left to the judgment of the local investigators. Fourth, we could 272 
not address the issue of lesion progression of LMCA and ostial LCX, since we did not evaluate the 273 
follow-up angiograms. Fifth, because we could not fully monitor the study patients, there is 274 
potential for under-reporting adverse events with potential for bias. Finally, although this is the 275 
largest series of patients undergoing SES implantation for the ostial LAD lesions, the study is 276 
obviously underpowered to evaluate potential small differences in clinical outcomes. Furthermore, 277 
16 
 
small numbers of events severely limit our ability to make adequate statistical adjustment by 278 
multivariable analysis. Therefore, the multivariable findings are exploratory due to the small 279 
sample size. 280 
Conclusions 281 
 In terms of both safety and efficacy, 3-year outcomes of PCI using SES for ostial LAD 282 
lesions were comparable to those for non-ostial proximal LAD lesions. Crossover-stenting across 283 
LCX with one-stent approach might be a reasonable option in treating ostial LAD lesions. The 284 
two-stent approach for bifurcation was associated with markedly higher rate of TLR than the 285 
one-stent approach.  286 
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Figure Legends 351 
Figure 1. Study flow chart for the current analysis among patients enrolled in the j-Cypher registry. 352 
LAD = left anterior descending coronary artery, and SES = sirolimus-eluting stent. 353 
 354 
Figure 2. Cumulative incidences of target lesion revascularization and death or myocardial 355 
infarction: ostial LAD lesions vs. non-ostial proximal LAD lesions.  356 
LAD = left anterior descending coronary artery, and SES = sirolimus-eluting stent. 357 
 358 
Figure 3. Cumulative incidences of target lesion revascularization and death or myocardial 359 
infarction among patients treated for ostial left anterior descending coronary artery lesions: 360 
one-stent vs. two-stent approach. 361 
SES = sirolimus-eluting stent. 362 
 363 
Figure 4. Cumulative incidences of target lesion revascularization and death or myocardial 364 
infarction among patients treated for ostial left anterior descending coronary artery lesions with 365 
one-stent approach: crossover-stenting vs. ostial-stenting. 366 





Table 1. Baseline Characteristics of Patients Treated for Ostial LAD Lesion as Compared With 370 
Non-ostial Proximal LAD Lesion 371 
(A) Patient characteristics       
  Ostial LAD Non-ostial Proximal LAD P value 
Number of patients 481 5369  
Age (years) 68.9±10.8 68.1±10.4 0.14 
Age >= 80 years 84 (17%) 700 (13%) 0.006 
Male 365 (76%) 3933 (73%) 0.21 
Body mass index 23.7±3.2 24.0±3.4 0.046 
 Body mass index < 25.0 331 (69%) 3461 (64%) 0.06 
Hypertension 341 (71%) 4023 (75%) 0.051 
Diabetes mellitus 193 (40%) 2150 (40%) 0.97 
Diabetes mellitus on insulin therapy 37 (7.7%) 468 (8.7%) 0.44 
Current smoking 91 (19%) 1121 (21%) 0.31 
Statin use 231 (48%) 2278 (42%) 0.02 
eGFR (mL/min/1.73m2) 59.1±21.8 59.7±22.7 0.56 
eGFR < 30, without hemodialysis 23 (4.8%) 248 (4.6%) 0.87 
Hemodialysis 18 (3.7%) 235 (4.4%) 0.51 
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Acute coronary syndrome 127 (26%) 1479 (28%) 0.59 
   STEMI 37 (7.7%) 619（12%） 0.01 
   NSTEMI 11 (2.3%) 124 (2.3%) 0.97 
Prior myocardial infarction  142 (30%) 1252 (23%) 0.002 
Prior Stroke 45 (9.4%) 498 (9.3%) 0.95 
Peripheral vascular disease 56 (12%) 548 (10%) 0.32 
Prior heart failure 62 (13%) 746 (14%) 0.54 
Multi-vessel disease 240 (50%) 2806 (52%) 0.32 
Ejection fraction <= 40% 52 (12%) 521 (11%) 0.49 
(B) Lesion and procedural characteristics       
Number of lesions 481 5369  
De novo lesion 343 (71%) 4084 (76%) 0.02 
In-stent restenosis 76 (16%) 691 (13%) 0.07 
Chronic total occlusion 45 (9.4%) 403 (7.5%) 0.14 
Severe calcification 53 (11%) 583 (11%) 0.91 
Lesion length >= 30mm 92 (19%) 882 (17%) 0.15 
Reference vessel diameter pre < 2.5mm 76 (16%) 1504 (28%) <0.0001 
Use of intravascular ultrasound 351 (73%) 2579 (48%) <0.0001 
Direct stenting 94 (20%) 1269 (24%) 0.04 
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Atherectomy before stenting    
 Directional coronary atherectomy 41(8.5%) 14 (0.3%) <0.0001 
 Rotational atherectomy 32 (6.7%) 313 (5.8%) 0.46 
Post dilatation 296 (62%) 2513 (47%) <0.0001 
Maximum inflation pressure (atm) 18.4±2.8 18.0±3.2 0.008 
Number of stents used 1.6±0.8 1.4±0.7 <0.0001 
Length of stents used (mm) 33.2±19.9 30.4±16.0 0.0003 
Maximum stent size (mm) 3.2±0.3 3.0±0.3 <0.0001 
Maximum balloon size (mm) 3.4±0.4 3.0±0.4 <0.0001 
Quantitative coronary angiographic data    
 Lesion length (mm) 19.4±13.8 19.9±11.7 0.45 
 Reference vessel diameter pre (mm) 2.99±0.55 2.73±0.49 <0.0001 
 Minimal lumen diameter pre (mm) 0.68±0.50 0.63±0.44 0.009 
 Diameter stenosis pre (%) 77.4±16.2 76.9±15.9 0.56 
 Reference vessel diameter post (mm) 3.25±0.48 2.94±0.43 <0.0001 
 Minimal lumen diameter post (mm) 2.95±0.55 2.68±0.47 <0.0001 
 Diameter stenosis post (%) 9.5±9.7 8.8±9.8 0.13 
Data was missing for body mass index in 2 patients, for body mass index<25.0 in 2 patients, for 372 
statin use in 49 patients, for eGFR in 1 patient, for eGFR < 30, without hemodialysis in 1 patient, 373 
for ejection fraction <= 40% in 723 patients, de novo lesion in 1 lesion, in-stent restenosis in 1 374 
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lesion, chronic total occlusion in 14 lesions, lesion length >= 30mm in 68 lesions, reference vessel 375 
diameter pre < 2.5mm in 63 lesions, use of intravascular ultrasound in 17 lesions, direct stenting in 376 
7 lesions, post dilatation in 9 lesions, maximum inflation pressure in 43 lesions, lesion length in 68 377 
lesions, reference vessel diameter pre in 63 lesions, minimal lumen diameter pre in 63 lesions, 378 
diameter stenosis pre in 22 lesions, reference vessel diameter post in 53 lesions, minimal lumen 379 
diameter post in 53 lesions, and diameter stenosis post in 23 lesions. 380 
eGFR = estimated glomerular filtration rate, LAD = left anterior descending coronary artery, 381 




Table 2. Unadjusted and Adjusted Outcomes Through 3 Years in Patients Treated for Ostial LAD 384 
Lesion as Compared With Non-ostial Proximal LAD Lesion 385 
  Ostial LAD Non-ostial Proximal LAD   Multivariable   
 (N=481) (N=5369)    
 N of events (Incidence) N of events (Incidence) p value HR (95%CI) p value 
All-cause death  40 (9.7%) 397 (9.2%) 0.51 1.13 (0.8-1.54) 0.48 
Cardiac death  18 (4.5%) 205 (4.7%) 0.92 1.05 (0.62-1.66) 0.84 
Sudden death  4 (1.2%) 70 (1.6%) 0.37 0.69 (0.21-1.67) 0.45 
Myocardial infarction 11 (2.7%) 171 (4.0%) 0.26 0.73 (0.37-1.28) 0.29 
Stroke 23 (5.9%) 178 (4.2%) 0.09 1.38 (0.86-2.09) 0.17 
Definite/Probable ST 5 (1.2%) 68 (1.6%) 0.65 0.82 (0.29-1.84) 0.66 
Definite ST 4 (1.0%) 60 (1.4%) 0.55 0.77 (0.23-1.86) 0.59 
TLR 38 (9.4%) 426 (9.7%) 0.98 0.99 (0.7-1.36) 0.94 
CABG 5 (1.2%) 66 (1.4%) 0.73 1.03 (0.36-2.35) 0.94 
Any coronary revascularization 110 (27.0%) 1372 (29.5%) 0.21 0.91 (0.74-1.1) 0.33 
Death/Myocardial infarction 45 (10.7%) 480 (11.4%) 0.82  1.05 (0.76-1.4) 0.77 
Incidence was estimated by Kaplan-Meier method. 386 
CABG=coronary artery bypass grafting, CI=confidence interval, HR=hazard ratio, LAD=left 387 
anterior descending coronary artery, ST=stent thrombosis, and TLR=target-lesion revascularization 388 
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 Table 3. Unadjusted and Adjusted Outcomes Through 3 Years in Patients with Ostial LAD Lesions 389 
Treated by One-stent Approach as Compared With Those Treated by the Two-stent Approach. 390 
  One-stent approach Two-stent approach   Multivariable   
 (N=419) (N=62)    
 N of events (Incidence) N of events (Incidence) p value HR (95%CI) p value 
All-cause death  32 (8.6%) 8 (16.8%) 0.2  1.3 (0.54-2.83) 0.54 
Cardiac death  14 (3.6%) 4 (10.5%) 0.24  0.92 (0.25-2.79) 0.89 
Sudden death  3 (0.9%) 1 (4.0%) 0.47   
Myocardial infarction 10 (2.8%) 1 (2.1%) 0.69 0.66 (0.04-3.46) 0.68 
Stroke 16 (4.7%) 7 (1.4%) 0.01 3.38 (1.3-7.93) 0.01 
Definite/Probable ST 4 (1.1%) 1 (2.1%) 0.64   
Definite ST 3 (0.8%) 1 (2.1%) 0.48    
TLR 22 (6.6%) 16 (28.1%) <0.0001 4.65 (2.32-9.25) <0.0001 
CABG 1 (0.3%) 4 (7.4%) <0.0001   
Any coronary revascularization 85 (24.3%) 25 (44.7%) <0.0001 2.11 (1.3-3.33) 0.003 
Death/Myocardial infarction 37 (9.8%) 8 (16.8%) 0.37 1.15 (0.49-2.41) 0.73 
Incidence was estimated by Kaplan-Meier method. 391 




Table 4. Unadjusted and Adjusted Outcomes Through 3 Years in Patients with One-stent Approach 394 
Treated by Ostial-stenting Technique as Compared With Those Treated by Crossover-stenting 395 
Technique  396 
  Ostial-Stenting Crossover-Stenting   Multivariable   
 (N=194) (N=225)    
 N of events (Incidence) N of events (Incidence) p value HR (95%CI) p value 
All-cause death  8 (4.5%) 24 (12.2%) 0.01 2.04 (0.94-4.93) 0.07 
Cardiac death  3 (1.7%) 11 (5.2%) 0.06 1.7 (0.49-7.85) 0.42 
Sudden death  0 (0%) 3 (1.6%) 0.1    
Myocardial infarction 6 (3.6%) 4 (2.0%) 0.41 0.59 (0.15-2.07) 0.41 
Stroke 8 (4.8%) 8 (4.6%) 0.84 0.87 (0.32-2.38) 0.79 
Definite/Probable ST 1 (0.5%) 3 (1.6%) 0.37   
Definite ST 1 (0.5%) 2 (1.1%) 0.62   
TLR 11 (7.9%) 11 (5.4%) 0.81 0.77 (0.33-1.82) 0.55 
CABG 0 (0%) 1 (0.5%) 0.35   
Any coronary revascularization 41 (25.1%) 44 (23.5%) 0.8  0.93 (0.61-1.42) 0.73 
Death/Myocardial infarction 12 (7.0%) 25 (12.2%) 0.07 1.54 (0.78-3.2) 0.22 
Incidence was estimated by Kaplan-Meier method. 397 



















Figure 4. 409 
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